American Healthcare REIT, Inc. (AHR)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at American Healthcare REIT, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 55.10 $ — 86% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AAQS
5/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 9.7%
- Exp. sales growth 3Y > 5% 16.2%
- EBIT growth 10Y > 5% 1.1%
- Exp. EBIT growth 3Y > 5% 43.4%
- Net debt < 4x EBIT 9.4x
- EBIT positive, 10Y straight 10
- Max. EBIT decline < 50% 59.5%
- Return on equity > 15% 2.5%
- ROCE > 15% 3.7%
- Expected return > 10% 45.5%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 11.8% failed
- More than 10% revenue growth is expected for the coming year 11.0% passed
- Share count grows by less than 3% a year 36.1% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 16.5% failed
- Gross margin at 40% or higher and without meaningful erosion 1.8% failed
- Goodwill from acquisitions does not grow faster than revenue 4.3% passed
- Net debt below twice EBITDA 4.9 x EBITDA failed
- Operating cash flow covers the profits of the last three years 609 m passed
- Return on capital at 15% or higher, or up versus two years ago 3.7% passed
- Insiders hold at least 10% or are net buyers 0.8% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 9.6% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 9
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.55 | 0.55 – 0.55 | 2,729 | -19.3% | 1 |
| 12/31/2027 | 0.86 | 0.82 – 0.90 | 3,054 | 56.4% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.51 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.21 | – | 543 | 12.50 | -5.90 | 60 | 30 |
| 2025: Q1 | -0.04 | – | 541 | 8.20 | -1.30 | 61 | 39 |
| 2025: Q2 | 0.06 | 306.00 | 543 | 7.50 | 1.80 | 72 | 45 |
| 2025: Q3 | 0.34 | – | 573 | 9.40 | 9.80 | 107 | 155 |
| 2025: Q4 | 0.06 | – | 604 | 11.30 | 1.80 | 55 | -14 |
| 2026: Q1 | 0.13 | – | 651 | 20.40 | 3.60 | 88 | 50 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 980 | 152 | -146 | -3.01 | 114 | 1,263 | 2,795 |
| 2017 | 1,049 | 179 | 11 | 0.23 | 128 | 1,188 | 2,800 |
| 2018 | 1,131 | 179 | 13 | 0.27 | 107 | 1,061 | 2,889 |
| 2019 | 1,221 | 190 | -5 | -0.11 | 117 | 901 | 3,172 |
| 2020 | 1,185 | 132 | 2 | 0.03 | 219 | 866 | 3,235 |
| 2021 | 1,264 | 139 | -48 | -0.72 | 18 | 1,581 | 4,580 |
| 2022 | 1,618 | 91 | -81 | -1.23 | 148 | 1,400 | 4,787 |
| 2023 | 1,859 | 77 | -71 | -1.08 | 99 | 1,270 | 4,578 |
| 2024 | 2,071 | 137 | -38 | -0.29 | 176 | 2,261 | 4,488 |
| 2025 | 2,260 | 168 | 70 | 0.42 | 294 | 3,321 | 5,426 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
American Healthcare REIT, Inc., ein selbstverwalteter REIT aus Maryland, besitzt und betreibt ein diversifiziertes Portfolio klinischer Gesundheitsimmobilien in den USA.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 121 |
| Headquarters | Irvine, CA |
| Address | 18191 Von Karman Avenue, 92612-7106 Irvine, United States |
| Phone | 949 270 9200 |
| Website | americanhealthcarereit.com |
| IPO Date | 7. Feb 2024 |
| ISIN | US3981823038 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jeffrey T. Hanson | CEO & Chairman | – |
| Gabe M. Willhite | President & COO | – |
| Mark E. Foster | Executive VP, General Counsel & Secretary | – |
| Brian S. Peay | Chief Financial Officer | – |
| Stefan K.L Oh | Chief Investment Officer | – |
| Kenny Lin | Executive VP, Deputy CFO & Chief Accounting Officer | – |
| Cora Lo | Senior VP, Associate General Counsel & Assistant Secretary | – |
| Wendie Newman | Executive Vice President of Asset Management | – |
| Raymond Oborn | Executive Vice President of Asset Management | – |
| Charlynn Diapo | Senior VP of Accounting & Finance | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 21. Jul 2026 | Prosky Danny | Director | Other | 2,594 | 0.00 | – |
| 21. Jul 2026 | Prosky Danny | Director | Other | 11,283 | 56.66 | 639,295 |
| 21. Jul 2026 | Prosky Danny | Director | Other | 20,912 | – | – |
| 21. Jul 2026 | Prosky Danny | Director | Other | 16,663 | 56.66 | 944,126 |
| 21. Jul 2026 | Prosky Danny | Director | Other | 30,886 | – | – |
| 21. Jul 2026 | Prosky Danny | Director | Other | 59,945 | 56.66 | 3,396,484 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.